Northeast Investment Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.39M Buy
57,478
+8,786
+18% +$1.03M 0.27% 58
2026
Q1
$5.86M Buy
48,692
+1,391
+3% +$161K 0.24% 60
2025
Q4
$4.98M Buy
47,301
+2,568
+6% +$241K 0.19% 63
2025
Q3
$3.75M Sell
44,733
-2,029
-4% -$167K 0.15% 69
2025
Q2
$3.7M Sell
46,762
-7,089
-13% -$563K 0.16% 68
2025
Q1
$4.83M Sell
53,851
-10,705
-17% -$999K 0.23% 61
2024
Q4
$6.42M Buy
64,556
+714
+1% +$73.6K 0.29% 60
2024
Q3
$7.25M Buy
63,842
+2,423
+4% +$288K 0.32% 58
2024
Q2
$7.6M Buy
61,419
+1,818
+3% +$234K 0.36% 56
2024
Q1
$7.86M Buy
59,601
+2,996
+5% +$369K 0.39% 54
2023
Q4
$6.17M Sell
56,605
-4,612
-8% -$479K 0.33% 57
2023
Q3
$6.3M Buy
61,217
+821
+1% +$88.5K 0.37% 56
2023
Q2
$6.97M Sell
60,396
-107
-0.2% -$12.1K 0.39% 54
2023
Q1
$6.44M Buy
60,503
+38
+0.1% +$4.1K 0.39% 53
2022
Q4
$6.71M Sell
60,465
-1,784
-3% -$182K 0.43% 52
2022
Q3
$5.36M Buy
62,249
+467
+0.8% +$41.7K 0.36% 56
2022
Q2
$5.63M Sell
61,782
-515
-0.8% -$45.7K 0.36% 53
2022
Q1
$5.11M Sell
62,297
-1,133
-2% -$89.3K 0.27% 58
2021
Q4
$4.86M Buy
63,430
+151
+0.2% +$12K 0.24% 61
2021
Q3
$4.75M Sell
63,279
-4,908
-7% -$373K 0.25% 61
2021
Q2
$5.3M Sell
68,187
-30,428
-31% -$2.26M 0.29% 58
2021
Q1
$7.25M Sell
98,615
-2,126
-2% -$157K 0.43% 50
2020
Q4
$7.86M Sell
100,741
-4,883
-5% -$373K 0.48% 46
2020
Q3
$8.36M Buy
105,624
+2,744
+3% +$215K 0.56% 42
2020
Q2
$7.59M Buy
102,880
+7,323
+8% +$551K 0.57% 43
2020
Q1
$7.01M Sell
95,557
-3,438
-3% -$270K 0.64% 39
2019
Q4
$8.59M Buy
98,995
+3,641
+4% +$299K 0.63% 47
2019
Q3
$7.66M Buy
95,354
+4,201
+5% +$337K 0.61% 45
2019
Q2
$7.29M Buy
91,153
+33,975
+59% +$2.6M 0.58% 45
2019
Q1
$4.54M Buy
57,178
+3,737
+7% +$280K 0.38% 60
2018
Q4
$3.9M Buy
53,441
+11,426
+27% +$807K 0.38% 61
2018
Q3
$2.84M Sell
42,015
-460
-1% -$29.3K 0.23% 71
2018
Q2
$2.46M Buy
42,475
+8,168
+24% +$461K 0.21% 74
2018
Q1
$1.78M Sell
34,307
-1,442
-4% -$77.9K 0.16% 82
2017
Q4
$1.92M Sell
35,749
-849
-2% -$47.1K 0.16% 83
2017
Q3
$2.24M Buy
36,598
+6,131
+20% +$372K 0.2% 77
2017
Q2
$1.86M Sell
30,467
-1,386
-4% -$84.4K 0.17% 81
2017
Q1
$1.93M Buy
31,853
+1,084
+4% +$65.8K 0.18% 78
2016
Q4
$1.73M Buy
30,769
+2,975
+11% +$174K 0.17% 82
2016
Q3
$1.66M Buy
27,794
+1,497
+6% +$87.5K 0.17% 84
2016
Q2
$1.45M Buy
26,297
+303
+1% +$16.1K 0.15% 83
2016
Q1
$1.31M Buy
25,994
+3,418
+15% +$167K 0.13% 85
2015
Q4
$1.14M Buy
22,576
+499
+2% +$25.2K 0.12% 89
2015
Q3
$1.04M Sell
22,077
-137
-0.6% -$7.28K 0.11% 94
2015
Q2
$1.21M Buy
22,214
+791
+4% +$44.4K 0.12% 93
2015
Q1
$1.18M Buy
21,423
+48
+0.2% +$2.72K 0.12% 94
2014
Q4
$1.16M Buy
21,375
+64
+0.3% +$3.57K 0.11% 97
2014
Q3
$1.21M Buy
21,311
+564
+3% +$31.7K 0.12% 99
2014
Q2
$1.15M Buy
20,747
+3,218
+18% +$176K 0.12% 99
2014
Q1
$950K Buy
17,529
+751
+4% +$38.9K 0.1% 107
2013
Q4
$801K Buy
16,778
+1,238
+8% +$56.6K 0.09% 103
2013
Q3
$706K Buy
15,540
+4,579
+42% +$209K 0.09% 104
2013
Q2
$486K Buy
+10,961
New +$490K 0.06% 112

Other funds holding MRK

Northeast Investment Management's MRK Position: Q2 2026 in Review

Northeast Investment Management increased its Merck (MRK) stake by 18% in Q2 2026, buying an estimated $1.03M and bringing the position to 57,478 shares worth $7.39M. The position accounts for 0.27% of the portfolio, ranked #58.

Northeast Investment Management first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.59M in Q4 2019. 1,305 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Northeast Investment Management held 57,478 shares of Merck worth $7.39M as of Q2 2026.
  • Northeast Investment Management bought 8,786 Merck shares in Q2 2026, an estimated $1.03M.
  • Merck made up 0.27% of Northeast Investment Management's portfolio in Q2 2026, its #58 holding.
  • Northeast Investment Management first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Northeast Investment Management's Merck position peaked at $8.59M in Q4 2019.
  • 1,305 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Northeast Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.